Bactericidal activity and inhibition of tobramycin by DNA and F-actin.

<p>Bactericidal concentrations of free tobramycin (F-TOB), and liposomal tobramycin (L-TOB) at 2 mg/L were incubated with <i>P. aeruginosa</i> (ATCC 27853), or in presence of DNA/F-actin (125 to 1000 mg/L). Growth controls are represented at 0 h (empty bar), and 3 h (dark bar). Comparisons between free and liposomal tobramycin was made by ANOVA one-way post <i>t</i>-test, and <i>P</i>-values were considered significant when (***) <i>p</i><0.001.</p

Bactericidal activity and inhibition of antibiotics by DNA, F-actin, LPS and LTA.

<p>A) Bactericidal concentrations of free tobramycin (F-TOB) and liposomal tobramycin (L-TOB) were incubated in presence of LPS/LTA (1 to 1000 mg/L). B) Bactericidal concentrations of free polymyxin B (F-PMB) and liposomal polymyxin B (L-PMB) were incubated in presence of DNA/F-actin/LPS/LTA (125 to 1000 mg/L). Growth controls are represented at 0 h (empty bar), and 3 h (dark bar). Comparisons between free and liposomal formulations were made by ANOVA one-way post <i>t</i>-test, and <i>P</i>-values were considered significant when (**) <i>p</i><0.01, (***) <i>p</i><0.001.</p

Liposome-entrapped antibiotic stability assayed by microbiological assay.

<p>The stability of the liposomal formulations were examined at 37°C in an 18 h period in the presence of PBS, CAMH broth, supernatant of biofilm forming <i>P. aeruginosa</i>, a combination of DNA, F-actin, LPS, and LTA, and diluted intact or autoclaved sputum.</p

Bactericidal activity and inhibition of antibiotics by LPS and LTA.

<p>A) Bactericidal concentrations of free tobramycin (F-TOB) and liposomal tobramycin (L-TOB) were incubated in presence of LPS/LTA (1 to 1000 mg/L). B) Bactericidal concentrations of free polymyxin B (F-PMB) and liposomal polymyxin B (L-PMB) were incubated in presence of LPS/LTA (1 to 1000 mg/L). Growth controls are represented at 0 h (empty bar), and 3 h (dark bar). Comparisons between free and liposomal formulations were made by ANOVA one-way post <i>t</i>-test, and <i>P</i>-values were considered significant when (***) <i>p</i><0.001.</p

CF Sputum treatment with various antibiotic formulations.

<p>CFU counts were made after incubation of diluted CF sputum (1∶10 w/v) in PBS with two-fold dilutions of free tobramycin at 512 mg/L (F-TOB), liposomal tobramycin at 128 mg/L (L-TOB), free polymyxin B at 32 mg/L (F-PMB), and liposomal polymyxin B at 8 mg/L (L-PMB). Growth controls are represented at 0 h (empty bar), and 18 h (dark bar).</p

Minimum Bactericidal Concentrations.

<p>Bactericidal activity of free and liposomal formulations against susceptible <i>P. aeruginosa</i> ATCC 27853 strain was carried out in broth alone or in presence of DNA/F-actin/LPS/LTA at a final concentration of 1000 mg/L.</p